Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
BeOne Medicines Ltd.
ISIN CH1391448177
|WKN A41ANK
Market cap (in EUR)
31,972 m
Country
Switzerland
Sector
Healthcare
Overview
Description
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Switzerland
Financials
Key metrics
| Market capitalisation, EUR | 31,972 m |
| EPS, EUR | 0.17 |
| P/B ratio | 7.8 |
| P/E ratio | 121.9 |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 4,736 m |
| Net income, EUR | 254 m |
| Profit margin | 5.37% |
What ETF is BeOne Medicines Ltd. in?
There are 15 ETFs which contain BeOne Medicines Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of BeOne Medicines Ltd. is the iShares China Large Cap UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.